TFFP News and Press, TFF Pharmaceuticals Inc - Ordinary Shares From 03/19/20

Company to hold conference call and webcast at 8:30 AM EDT TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today a...

Successfully completes single ascending dose phase of first clinical study in healthy subjects for a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation Invasive Pulmonary Aspergillosis is a severe fungal pulmonary disease with a mortality rate that can reach 90 percent&#x...

  TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged J.S. Cole & ...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that the Company has engaged Torreya Partners, LLC (Torre...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “TFFP utilizes its proprietary Thin Film Freezing (TFF) technology to develop improved versions of existing therapeutics through formulating...

The following slide deck was published by TFF Pharmaceuticals, Inc. in conjunction with this Read more ...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announced today that Malcolm Fairbairn has been appointed to the Board of...

Continued clinical progress with lead compound Voriconazole Inhalation Powder, to treat invasive pulmonary aspergillosis (IPA) Tacrolimus Inhalation Powder for immunosuppression in transplant medicine expected to begin Phase 1 dosing in Q1-2020 Initiates collaboration and feas...

University of Texas at Austin professor named one of the National Academy of Inventors Fellows for 2019 TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Fil...

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that it will be meeting with investors and commercial par...